Clinical trials: Hormone Refractory
Prostate Cancer
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with…
- Trial name
- NCT00004014
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Prostate Cancer
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416533
- Testing
- docetaxel, doxorubicin hydrochloride, prednisone
- Volunteers
- 47 people
- Sponsor
- Wake Forest University Health Sciences
Hormone-refractory Prostate Cancer
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
Prostate cancer is the most common non-skin tumor diagnosed in men and the second leading cause of cancer death in men in Western countries.
- Trial name
- PREMIERE (NCT02288936)
- Testing
- Enzalutamide
- Where
- 16 sites in Spain
- Volunteers
- 98 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Prostate Cancer
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status.
- Trial name
- NCT00545766
- Testing
- Vinflunine
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Prostate Cancer, Hormone Refractory Prostate Cancer
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory…
- Trial name
- NCT00069745
- Testing
- Satraplatin, Prednisone
- Where
- 211 sites in United States, Argentina and 13 more
- Sponsor
- Agennix
Hormone Refractory Prostate Cancer
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.
- Trial name
- APP22 (NCT00583024)
- Testing
- ADENOVIRUS/PSA VACCINE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- David M Lubaroff
Leukemia, Myeloid, Chronic, Anemia, Aplastic
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to…
- Conditions
- Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma
- Trial name
- NCT00393380
- Testing
- Parathyroid Hormone (teriparatide)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- The Emmes Company, LLC
Prostate Cancer
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells.
- Trial name
- NCT00006002
- Testing
- dexamethasone, semaxanib
- Where
- 18 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Prostatic Neoplasms
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.
- Trial name
- NCT00280098
- Testing
- docetaxel
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Sanofi
Hormone Refractory Prostate Cancer
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory)…
- Trial name
- NCT00928252
- Testing
- IV fluorine-18 labeled methylcholine before PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Queen's Medical Center
Castration-Resistant Prostatic Cancer
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life…
- Trial name
- PARABO (NCT02398526)
- Testing
- Radium-223 dichloride, (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Bayer
Prostate Cancer
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or…
- Trial name
- NCT00286793
- Testing
- AT-101
- Where
- 13 sites in United States
- Volunteers
- 76 people
- Sponsor
- Ascenta Therapeutics
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Hormone Refractory Prostate Cancer Disease
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability…
- Trial name
- NCT00419536
- Testing
- LBH589
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following…
- Trial name
- NCT00124566
- Testing
- Irofulven, Prednisone, Mitoxantrone
- Where
- 50 sites in United States, Brazil and 7 more
- Volunteers
- 135 people
- Sponsor
- Eisai Inc.
Prostate Cancer
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with…
- Trial name
- NCT00314782
- Testing
- ZD4054 (Zibotentan), Docetaxel
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Hormone Refractory Prostate Cancer
RNActive®-Derived Therapeutic Vaccine
This is a Phase I/IIa open, uncontrolled, prospective study, to be conducted in an out-patient setting. The present study is one of two clinical trials of the RNActive®-derived vaccine CV9103 being conducted concurrently in the…
- Trial name
- NCT00906243
- Testing
- CV9103
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Prostatic Neoplasms
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT00537381
- Testing
- Docetaxel, Prednisone, Intetumumab
- Where
- 59 sites in United States, Austria and 8 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.